Suppr
超能文献

Strengthening the sting of immunotherapy.

作者信息

Crunkhorn Sarah

机构信息

Senior Editor, Nature Reviews Drug Discovery, .

出版信息

Nat Rev Immunol. 2020 Oct;20(10):589. doi: 10.1038/s41577-020-00447-1.

DOI:10.1038/s41577-020-00447-1

PMID:32901152

Abstract

摘要

相似文献

Strengthening the sting of immunotherapy.

Nat Rev Immunol. 2020 Oct;20(10):589. doi: 10.1038/s41577-020-00447-1.

Strengthening the sting of immunotherapy.

Nat Rev Drug Discov. 2020 Oct;19(10):669. doi: 10.1038/d41573-020-00148-3.

Survey of patients after discontinuing venom immunotherapy.

J Allergy Clin Immunol. 2000 Feb;105(2 Pt 1):385-90. doi: 10.1016/s0091-6749(00)90092-7.

Discontinuation of yellow jacket venom immunotherapy: follow-up of 75 patients by means of deliberate sting challenge.

J Allergy Clin Immunol. 1997 Dec;100(6 Pt 1):767-70. doi: 10.1016/s0091-6749(97)70271-9.

The discovery of potent small molecule activators of human STING.

Eur J Med Chem. 2021 Jan 1;209:112869. doi: 10.1016/j.ejmech.2020.112869. Epub 2020 Sep 30.

Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.

J Allergy Clin Immunol. 2001 Dec;108(6):1027-32. doi: 10.1067/mai.2001.119154.

Basophil response and the induction of a tolerance in venom immunotherapy: a long-term sting challenge study.

Allergy. 2012 Jun;67(6):822-30. doi: 10.1111/j.1398-9995.2012.02817.x. Epub 2012 Apr 3.

Multifunctional STING-Activating Mn O @Au-dsDNA/DOX Nanoparticle for Antitumor Immunotherapy.

Adv Healthc Mater. 2020 Jul;9(13):e2000064. doi: 10.1002/adhm.202000064. Epub 2020 Jun 2.

Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions.

Curr Top Med Chem. 2019;19(3):180-185. doi: 10.2174/1568026619666190308131805.

Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy.

Clin Exp Allergy. 2003 Sep;33(9):1216-20. doi: 10.1046/j.1365-2222.2003.01755.x.

引用本文的文献

Nanocarrier-mediated modulation of cGAS-STING signaling pathway to disrupt tumor microenvironment.

Naunyn Schmiedebergs Arch Pharmacol. 2025 Feb 5. doi: 10.1007/s00210-025-03835-3.

Targeted Delivery of STING Agonist via Albumin Nanoreactor Boosts Immunotherapeutic Efficacy against Aggressive Cancers.

Pharmaceutics. 2024 Sep 17;16(9):1216. doi: 10.3390/pharmaceutics16091216.

Overcoming pancreatic cancer immune resistance by codelivery of CCR2 antagonist using a STING-activating gemcitabine-based nanocarrier.

Mater Today (Kidlington). 2023 Jan-Feb;62:33-50. doi: 10.1016/j.mattod.2022.11.008. Epub 2022 Dec 8.

Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation.

Adv Sci (Weinh). 2022 Dec;9(35):e2204335. doi: 10.1002/advs.202204335. Epub 2022 Oct 18.

Trial watch: intratumoral immunotherapy.

Oncoimmunology. 2021 Oct 15;10(1):1984677. doi: 10.1080/2162402X.2021.1984677. eCollection 2021.

Identification of MSA-2: An oral antitumor non-nucleotide STING agonist.

Signal Transduct Target Ther. 2021 Jan 12;6(1):18. doi: 10.1038/s41392-020-00459-2.

本文引用的文献

Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic.

Science. 2020 Aug 21;369(6506):993-999. doi: 10.1126/science.abb4255.

An orally available non-nucleotide STING agonist with antitumor activity.

Science. 2020 Aug 21;369(6506). doi: 10.1126/science.aba6098.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Strengthening the sting of immunotherapy.

Nat Rev Immunol. 2020 Oct;20(10):589. doi: 10.1038/s41577-020-00447-1.

Strengthening the sting of immunotherapy.

Nat Rev Drug Discov. 2020 Oct;19(10):669. doi: 10.1038/d41573-020-00148-3.

Survey of patients after discontinuing venom immunotherapy.

J Allergy Clin Immunol. 2000 Feb;105(2 Pt 1):385-90. doi: 10.1016/s0091-6749(00)90092-7.

Discontinuation of yellow jacket venom immunotherapy: follow-up of 75 patients by means of deliberate sting challenge.

J Allergy Clin Immunol. 1997 Dec;100(6 Pt 1):767-70. doi: 10.1016/s0091-6749(97)70271-9.

The discovery of potent small molecule activators of human STING.

Eur J Med Chem. 2021 Jan 1;209:112869. doi: 10.1016/j.ejmech.2020.112869. Epub 2020 Sep 30.

Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.

J Allergy Clin Immunol. 2001 Dec;108(6):1027-32. doi: 10.1067/mai.2001.119154.

Basophil response and the induction of a tolerance in venom immunotherapy: a long-term sting challenge study.

Allergy. 2012 Jun;67(6):822-30. doi: 10.1111/j.1398-9995.2012.02817.x. Epub 2012 Apr 3.

Multifunctional STING-Activating Mn O @Au-dsDNA/DOX Nanoparticle for Antitumor Immunotherapy.

Adv Healthc Mater. 2020 Jul;9(13):e2000064. doi: 10.1002/adhm.202000064. Epub 2020 Jun 2.

Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions.

Curr Top Med Chem. 2019;19(3):180-185. doi: 10.2174/1568026619666190308131805.

Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy.

Clin Exp Allergy. 2003 Sep;33(9):1216-20. doi: 10.1046/j.1365-2222.2003.01755.x.

引用本文的文献

Nanocarrier-mediated modulation of cGAS-STING signaling pathway to disrupt tumor microenvironment.

Naunyn Schmiedebergs Arch Pharmacol. 2025 Feb 5. doi: 10.1007/s00210-025-03835-3.

Targeted Delivery of STING Agonist via Albumin Nanoreactor Boosts Immunotherapeutic Efficacy against Aggressive Cancers.

Pharmaceutics. 2024 Sep 17;16(9):1216. doi: 10.3390/pharmaceutics16091216.

Overcoming pancreatic cancer immune resistance by codelivery of CCR2 antagonist using a STING-activating gemcitabine-based nanocarrier.

Mater Today (Kidlington). 2023 Jan-Feb;62:33-50. doi: 10.1016/j.mattod.2022.11.008. Epub 2022 Dec 8.

Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation.

Adv Sci (Weinh). 2022 Dec;9(35):e2204335. doi: 10.1002/advs.202204335. Epub 2022 Oct 18.

Trial watch: intratumoral immunotherapy.

Oncoimmunology. 2021 Oct 15;10(1):1984677. doi: 10.1080/2162402X.2021.1984677. eCollection 2021.

Identification of MSA-2: An oral antitumor non-nucleotide STING agonist.

Signal Transduct Target Ther. 2021 Jan 12;6(1):18. doi: 10.1038/s41392-020-00459-2.

本文引用的文献

Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic.

Science. 2020 Aug 21;369(6506):993-999. doi: 10.1126/science.abb4255.

An orally available non-nucleotide STING agonist with antitumor activity.

Science. 2020 Aug 21;369(6506). doi: 10.1126/science.aba6098.

Suppr超能文献

Strengthening the sting of immunotherapy.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译